Glycopeptides

Trimannosyldilysine (Man3Lys2) is a mannosyl glycopeptide that can be coupled to human placental p-glucocerebrosidase to enhance macrophage uptake.

Teicoplanin A3-1 is a degradation product of teicoplanins A2-1 to 5 (Item Nos. 20187, 20188, 20189, 20192). Teicoplanins are glycopeptide antibiotics produced by A. teichomyceticus that are broadly effective against Gram-positive bacteria in vitro.

Chloroorienticin A (A82846B) is a glycopeptide antibiotic. Chloroorienticin A exhibits excellent activity against staphylococci and streptococci.

IgA1 Peptide GN5 (TFA) is a synthetic glycopeptide and can be used for detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients.

Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity.

Neu5Gcα(2-6) N-Glycan-Asn is a glycopeptide. Neu5Gcα(2-6) N-Glycan-Asn can be used for various biochemical studies.

Balhimycin is a glycopeptide antibiotic, found from the fermentation broth of a Amycolatopsis sp. Balhimycin shows anti-bacterial activity against staphylococci and anaerobes.

Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy.

Parvodicin C3 is a glycopeptide antibiotic. Parvodicin C3 has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and Enterococcus faecalis.

Parvodicin C4 is a glycopeptide antibiotic. Parvodicin C4 has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and Enterococcus faecalis.

Helvecardin B is a glycopeptidtic antibiotic. Helvecardin B has strong activity of anti-aerobic and anaerobic Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.

Parvodicin B1 is a glycopeptide antibiotic. Parvodicin B1 has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and Enterococcus faecalis. Parvodicin B1 acts by inhibiting the synthesis of bacterial cell wall.

Parvodicin B2 is a glycopeptide antibiotic. Parvodicin B2 has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and Enterococcus faecalis. Parvodicin B2 acts by inhibiting the synthesis of bacterial cell wall.

Parvodicin A is a glycopeptide antibiotic. Parvodicin A has inhibitory effect on Staphylococcus aureus, Staphylococcus furfur, Staphylococcus hemolyticus and Enterococcus faecalis.

Helvecardin A is a glycopeptidtic antibiotic. Helvecardin A has strong activity of anti-aerobic and anaerobic Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.

N-Demethylvancomycin is a glycopeptide antibiotic which can be extracted from Nocardia orientalis and active against several strains of S. aureus and S. epidermidis. N-Demethylvancomycin can be used for infection research.

Teicoplanin A2-2 is a glycopeptide antibiotic. Teicoplanin A2-2 exhibits antibacterial activity, particularly against coagulase-negative staphylococci (CNS). Teicoplanin A2-2 inhibits bacterial cell wall synthesis by competitively binding to the terminal D-Ala-D-Ala peptide bonds in the cell wall synthesis process, leading to bacterial death. Teicoplanin A2-2 can be used for research into bacterial resistance mechanisms and the development of new antibiotics.